UESTC's Groundbreaking Entry into Top-Tier Life Sciences
The University of Electronic Science and Technology of China (UESTC), long renowned for its prowess in engineering and electronics, has marked a pivotal moment in its evolution toward interdisciplinary excellence. On February 27, 2026, researchers from UESTC's Medical School, in collaboration with the university's affiliated Sichuan Provincial People's Hospital, published a landmark paper as the first-author institution in the prestigious journal Cell. This achievement underscores UESTC's strategic push into life sciences and medicine, blending its computational strengths with biological innovation.
Titled "Pyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation," the study reveals a novel mechanism linking metabolism to immune response, with profound implications for understanding viral infections in diabetic patients. For a university traditionally focused on information technology, this publication signals a new era of cross-disciplinary research prowess.
The Discovery: Pyruvate's Unexpected Role in Immune Suppression
At the heart of the research is pyruvate, the end product of glycolysis—the process where glucose is broken down for energy. While pyruvate is well-known for fueling cellular respiration, the UESTC team uncovered its non-metabolic function: acting as a covalent modifier in a previously unknown post-translational modification termed protein pyruvylation.
Specifically, pyruvate binds to lysine 201 (K201) on STAT1 (Signal Transducer and Activator of Transcription 1), a critical protein in the Type I interferon (IFN-I) signaling pathway. This pathway is the body's primary defense against viruses, triggering antiviral gene expression upon infection. Pyruvylation creates steric hindrance, preventing STAT1 from dimerizing with STAT2, thus dampening IFN-I signaling and reducing antiviral immunity.
Under high-glucose conditions, mimicking hyperglycemia in diabetes, glycolysis accelerates, elevating pyruvate levels. Pyruvate kinase M2 (PKM2) catalyzes this pyruvylation, exacerbating immune suppression. Experiments with STAT1 K201R knock-in mice—where the modification site is mutated—demonstrated restored STAT1-STAT2 binding, heightened antiviral gene expression, lower viral loads, and improved survival rates post-infection.
Experimental Approaches: From High-Throughput Screening to In Vivo Validation
The study's rigor stems from multifaceted methods. Researchers began with RNA sequencing on cells exposed to high glucose, revealing upregulated glycolysis and suppressed IFN-I pathways. Systematic screening pinpointed pyruvate as the culprit, confirmed via PKM2 inhibition experiments.
Biotin-labeled pyruvate and mass spectrometry identified the STAT1 K201 site, with a characteristic 70.0468 Da mass shift verifying the covalent bond. Structural modeling via cryo-electron microscopy and molecular dynamics simulations illustrated the binding blockade.
- Cell lines (e.g., HEK293T, macrophages) treated with pyruvate showed dose-dependent IFN-I inhibition.
- Human peripheral blood mononuclear cells (PBMCs) from hyperglycemic donors exhibited higher pyruvate levels and pyruvylation, correlating with reduced IFN-stimulated genes.
- In vivo: Viral challenge models (e.g., VSV, influenza) in wild-type vs. K201R mice highlighted the modification's impact on survival and viral clearance.
These step-by-step validations established pyruvylation as a widespread modification across dozens of proteins, expanding its biological relevance.
Prof. Zheng Hui and the Trailblazing Team Behind the Breakthrough
Leading the effort is Prof. Hui Zheng (郑慧), a national-level talent at UESTC Medical School and Sichuan Provincial People's Hospital. Zheng's lab specializes in metabolic-immune crosstalk, leveraging UESTC's computational biology expertise. First author Yibo Zuo (左宜波), a PhD candidate, executed core experiments, marking a stellar contribution from young talent.
Collaborators included experts in proteomics, structural biology, and immunology, exemplifying UESTC's interdisciplinary ecosystem. Zheng noted, "High blood sugar populations are prone to severe viral outcomes, but the mechanism was unclear. Our discovery unveils pyruvate's dual role beyond metabolism."
This team's success reflects UESTC's investment in bio-medicine, with facilities like advanced imaging and high-throughput screening enabling such feats. Explore faculty positions at innovative Chinese universities like UESTC via our platform.
Implications for Diabetes, Viral Infections, and Beyond
Diabetes affects over 140 million in China, with hyperglycemia linked to severe COVID-19 and flu outcomes. This study elucidates the molecular link: pyruvate-mediated pyruvylation impairs IFN-I, heightening vulnerability.
- Clinical Relevance: Targets for therapies blocking pyruvylation or modulating pyruvate could bolster immunity in diabetics.
- Viral Pandemics: Insights for next-gen antivirals enhancing IFN-I without toxicity.
- Metabolic Diseases: Pyruvylation's broad occurrence suggests roles in cancer, neurodegeneration.
Potential interventions: PKM2 inhibitors or STAT1 mutants. This bridges metabolism and immunity, vital amid rising metabolic disorders.
UESTC's Rise in Biomedical Research: From Electronics to Cell
Founded in 1956, UESTC ranks among China's elite 'Double First-Class' universities, excelling in electronic information (top 3 globally). Its Medical School, established 2012, accelerates bio-interdisciplinary growth, with 200+ faculty and state-key labs.
Prior feats include Nature-index papers, but Cell marks the pinnacle. This aligns with China's 'Healthy China 2030,' emphasizing tech-med fusion. UESTC's computational tools (AI, big data) uniquely probe complex pathways like pyruvylation.
Check higher education opportunities in China or career advice for roles in rising bio hubs.
Broader Context: Interdisciplinary Trends in Chinese Higher Education
China's universities increasingly fuse engineering with biomedicine, per Ministry of Education initiatives. Tsinghua, PKU lead, but UESTC exemplifies regional powerhouses rising. From 2020-2025, bio papers from engineering unis surged 150%.
Challenges: Talent retention, funding. Solutions: UESTC's model—joint hospital-university labs, youth programs. This Cell paper inspires peers, boosting research assistant jobs in interdisciplinary fields.
Future Outlook: Therapeutic Horizons and Research Frontiers
Inhibitors targeting pyruvylation enter preclinical pipelines. UESTC plans follow-ups on pyruvylation in autoimmunity, aging. Zheng's team eyes clinical trials for diabetic antivirals.
For students/professionals: Interdisciplinary PhDs booming. UESTC offers programs blending AI, bio—ideal for scholarships seekers. Global collaborations accelerate translation.
Photo by Ray Graciano on Unsplash
Why This Matters for Global Academia and Health
UESTC's feat elevates China's higher ed profile, proving engineering roots fuel bio breakthroughs. For diabetics worldwide, it promises better viral protection. Aspiring researchers: Emulate via Rate My Professor, higher ed jobs, career advice.
Position yourself in China's bio revolution—browse university jobs or postdoc opportunities.